- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Insulet Corporation (PODD)
The Insulet share price today is 145.42, view NASDAQ PODD stock exchange data. Track the latest Insulet share price with real-time updates on PODD stock performance including market cap, day range, 52-week range and dividend yield. Access PODD charts, earnings dates and analyst estimates to support your investment decisions.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
145.15
151.75
52 wk Range
126.40
354.88
PODD is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
145.15151.75
52 wk Range
126.40354.88
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PODD Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
171.91
Upside
+18.22%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Management has been aggressively buying back shares
Why is Insulet stock sliding today?- Investing.com
Insulet Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
15 Buy
10 Hold
0 Sell
Ratings:
25 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 171.91
(+18.22% Upside)
Insulet Corporation SWOT Analysis
Patch Pump Pionee | Insulet leads the diabetes management market with innovative patch pump technology, boasting impressive financial health and a "GREAT" rating from InvestingPro |
Growth Trajectory | Explore Insulet's robust Q1 2025 performance, revised revenue guidance, and strategic expansion into Type 2 diabetes market, driving substantial growth |
Leadership Transition | New CEO Ashley McEvoy's appointment signals potential for accelerated growth and market expansion, despite initial investor uncertainty |
Market Valuation | Delve into Insulet's high valuation multiples, with analyst price targets ranging from $266 to $365, reflecting strong growth prospects in medical technology |
Insulet Corporation Earnings Call Summary for Q2/2026
- Insulet Q2 beat estimates with EPS of $1.66 vs. $1.45 expected, revenue $801.7M vs. $787.8M, but shares plunged 21% on reduced guidance.
- Company cut U.S. growth outlook to 17%-19% citing weaker retention and utilization in first 90 days among type 2 diabetes customers.
- Gross margin expanded 320bps to 72.9%; adjusted EPS rose 41.5% YoY, outpacing 23.5% revenue growth with strong operating leverage.
- International Omnipod revenue surged 35%, offsetting U.S. weakness; Q3 U.S. growth guidance lowered to 14%-16% from prior expectations.
- CEO McEvoy took accountability for missing retention issues; firm implementing enhanced customer support and sales incentive changes.
Last Updated: 05-08-2026, 06:46 pm
Read Full TranscriptEarnings
Latest Release
05-08-2026
EPS / Forecast
1.66 / 1.45
Revenue / Forecast
801.7M / 787.82M
Compare PODD to Peers and Sector
Metrics to compare | PODD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPODDPeersSector | |
|---|---|---|---|---|
P/E Ratio | 26.9x | −4.1x | −0.4x | |
PEG Ratio | 0.45 | 0.22 | 0.00 | |
Price/Book | 7.1x | 23.3x | 2.6x | |
Price / LTM Sales | 3.3x | 4.7x | 3.1x | |
Upside (Analyst Target) | 15.2% | 24.3% | 49.3% | |
Fair Value Upside | Unlock | −16.8% | 6.7% | Unlock |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Insulet (PODD) Share Price Today?
The Insulet share price today is 145.42.
What is the current Insulet (PODD) share price and day range?
As of 25-08-2026, the Insulet share price is 145.42, with a previous close of 145.42. The share price has ranged from 145.15 to 151.75 today, while the 52-week range spans from 126.40 to 354.88.
What Is the Insulet Market Cap?
As of today, Insulet market cap is 10.09B.
What Is the Insulet (PODD) Share Price Target?
The average 12-month share price target for Insulet is 171.91, with a high estimate of 275 and a low estimate of 144. 15 analysts recommend buying, while 0 suggest selling, with an overall rating of Buy and +18.22% Upside potential.
What Is Insulet's Earnings Per Share (TTM)?
The Insulet EPS (TTM) is 5.30.
When Is the Next Insulet Earnings Date?
Insulet will release its next earnings report on 29-10-2026.
From a Technical Analysis Perspective, Is PODD a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
What Stock Exchange Does Insulet Trade On?
Insulet is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Insulet?
The stock symbol for Insulet is "PODD."
How Many Times Has Insulet Stock Split?
Insulet has split 0 times.
How Many Employees Does Insulet Have?
Insulet has 5400 employees.
What Is the PODD Premarket Price?
PODD's last pre-market stock price is 151.51. The pre-market share volume is 6,410.00, and the stock has changed by 3.35, or 2.26%.
What Is the PODD After Hours Price?
PODD's last after hours stock price is 145.00, the stock has changed by -0.42, or -0.29%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.